|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4709 | (2006.01) |
| A61K 45/00 | (2013.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61K 45/00 | (2006.01) | ||
| A61K 39/395 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 31/4709 | (2013.01) | ||
| A61P 43/00 | (2006.01) | ||
| C07K 16/18 | (2013.01) | ||
| C07K 16/18 | (2006.01) | ||
| A61K 31/519 | (2013.01) |
| (11) | Number of the document | 3421039 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17756670.0 |
| Date of filing the European patent application | 2017-02-24 | |
| (97) | Date of publication of the European application | 2019-01-02 |
| (45) | Date of publication and mention of the grant of the patent | 2021-10-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/JP2017/007219 |
| Date | 2017-02-24 |
| (87) | Number | WO 2017/146236 |
| Date | 2017-08-31 |
| (30) | Number | Date | Country code |
| 2016035206 | 2016-02-26 | JP |
| (72) |
TANAKA, Kohei , JP
YASUHIRO, Tomoko , JP
|
| (73) |
ONO Pharmaceutical Co., Ltd. ,
1-5, Doshomachi 2-chome
Chuo-ku, Osaka-shi, Osaka 541-8526,
JP
|
| (54) | DRUG FOR CANCER THERAPY CHARACTERIZED BY ADMINISTERING COMBINATION BETWEEN AXL INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR |
| DRUG FOR CANCER THERAPY CHARACTERIZED BY ADMINISTERING COMBINATION BETWEEN AXL INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR |